Posted on February 9, 2021 by Sitemaster
The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 2, active, grade group, progression, surveillance | 9 Comments »
Posted on January 9, 2021 by Sitemaster
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
Posted on December 3, 2020 by Sitemaster
If you are one of our readers who is really “into” the underlying causes of and development of prostate cancer, then you probably want to see if you can read a newly published article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Uncategorized | Tagged: epigenetics, evolution, genetrics, initiation, progression | 2 Comments »
Posted on October 28, 2020 by Sitemaster
Perhaps unsurprisingly, your sitemaster was a little distracted on March 9 this year (by both the start of the COVID-19 chaos and by his birthday) and so he utterly missed what appears to be a rather important paper on the use of 5α-reductase inhibitors (5-ARIs) in men on active surveillance (AS) for management of low-risk forms of prostate cancer.
… READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, active, AS, Prevention, progression, surveillance | 2 Comments »
Posted on August 29, 2020 by Sitemaster
The Prostate Active Surveillance Study (PASS), initially funded by the Canary Foundation, is a multi-center research study for men with low-risk disease who have chosen active surveillance (AS) to manage their prostate cancer. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, AS, calculator, PASS, progression, risk, surveillance | Leave a comment »
Posted on March 5, 2019 by Sitemaster
A newly published article — and an associated editorial — in the Annals of Internal Medicine has addressed the possible benefits of taking low-dose aspirin as a method to prevent the progression of newly diagnosed prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: aspirin, outcome, Prevention, progression, risk | 7 Comments »
Posted on January 30, 2019 by Sitemaster
Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, monitoring, progression, risk, surveillance | 4 Comments »
Posted on June 1, 2018 by Sitemaster
In an incidentally timely manner, the May issue of Annals of Oncology carries a systematic review and meta-analysis of data on physical activity and risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: activity, Diagnosis, exercise, physical, Prevention, progression, risk | 1 Comment »
Posted on October 26, 2017 by Sitemaster
Back in 2011, what is now the Alliance for Clinical Trials in Oncology (ACTO) but was then CALGB (Cancer and Leukemia Group B) initiated the Men’s Eating and Living (MEAL) study. This trial is, we hope, going to give us some real answers to a very important question: does diet affect risk for the progression of prostate cancer in men on active surveillance? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, diet, progression, surveillance | Leave a comment »
Posted on September 30, 2017 by Sitemaster
A recent article in the Journal of Clinical Oncology, together with an associated editorial, have addressed the issue of whether evidence is now sufficient to argue that all men with prostate cancer should be treated with a statin. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: mortality, progression, risk, statin, Treatment | 8 Comments »
Posted on June 19, 2017 by Sitemaster
A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: active, age, progression, risk, surveillance | 6 Comments »
Posted on May 16, 2017 by Sitemaster
A new study just published in the World Journal of Urology has provided us with data from the Prostate Cancer Outcomes Registry — Victoria (in Australia) on the progression of men initially managed on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, progression, risk, surveillance, time, upgrading | 3 Comments »
Posted on November 14, 2016 by Sitemaster
One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, immunotherapy, metastasis, outcome, progression, sipuleucel-T, survival | 7 Comments »
Posted on November 7, 2016 by Sitemaster
According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: cell, circulating, CTC, metastasis, progression, risk, tumor | 3 Comments »
Posted on November 4, 2016 by Sitemaster
A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value. … READ MORE …
Filed under: Management, Prevention, Risk, Treatment | Tagged: delay, Prevention, progression, risk, statin | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 